Skin gadolinium following use of MR contrast agents in a rat model of nephrogenic systemic fibrosis.

PURPOSE To detect the ultrastructural site of gadolinium retention in skin by using an animal model of nephrogenic systemic fibrosis and compare a linear, low-stability gadolinium chelate (formulated gadodiamide) with a macrocylic, high-stability gadolinium chelate (gadoterate meglumine). MATERIALS AND METHODS Experimental procedures were performed according to rules and regulations laid down by the UK Home Office (Animal Procedures Act of 1986). Male Wistar rats were subjected to 5/6 subtotal nephrectomy (creatinine clearance, 25% normal). Gadolinium-based contrast agents, formulated gadodiamide (n = 9) and gadoterate meglumine (n = 11), were administered intravenously (2.5 mmol/kg for 5 days). After 28 days, skin was analyzed by means of morphometric and immunohistochemical techniques and electron microscopy. Data were compared with the Student t test. Skin gadolinium was located by means of energy-filtered transmission electron microscopy. RESULTS Formulated gadodiamide produced a 40-fold greater increase in gadolinium in skin than did gadoterate meglumine. An electron-dense filamentous material, detected within extracellular matrix, displayed a "halo" appearance, associated with collagen fibrils and electron-dense intracellular fragments of collagen fibrils within activated fibroblasts. Both electron-dense features demonstrated the presence of gadolinium but were much less apparent following gadoterate meglumine administration, where the presence of gadolinium was not detected. Formulated gadodiamide increased dermal cell count, dermal thickness, and collagen bundle density with enhanced immunostain for CD34, fibroblast-specific protein 1,4-hydroxy-prolyl-hydroxylase, and factor XIIIa. Circular staining for α-smooth muscle actin indicated new blood vessel formation. Skin of rats receiving gadoterate meglumine remained unchanged. CONCLUSION Gadolinium retention in skin following formulated gadodiamide administration was located to the collagen fibril, in both the extracellular matrix and within activated fibroblasts.

[1]  M. Port,et al.  Comparative In Vivo Dissociation of Gadolinium Chelates in Renally Impaired Rats: A Relaxometry Study , 2011, Investigative radiology.

[2]  S. Morcos.  Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far? , 2011, European Radiology.

[3]  C. Robic,et al.  Clinical, Biological, and Skin Histopathologic Effects of Ionic Macrocyclic and Nonionic Linear Gadolinium Chelates in a Rat Model of Nephrogenic Systemic Fibrosis , 2011, Investigative radiology.

[4]  C. Anderson,et al.  The biodistribution of [153Gd]Gd‐labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice , 2010, Magnetic resonance in medicine.

[5]  J. Vickers,et al.  The imbalanced expression of matrix metalloproteinases in nephrogenic systemic fibrosis. , 2010, Journal of the American Academy of Dermatology.

[6]  S. Morcos,et al.  Nephrogenic Gadolinium Biodistribution and Skin Cellularity Following a Single Injection of Omniscan in the Rat , 2010, Investigative radiology.

[7]  M. Perazella.  Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm , 2009, Current opinion in nephrology and hypertension.

[8]  S. Morcos,et al.  Interference of gadolinium-based contrast agents with the measurement of serum creatinine by the Jaffe reaction. , 2009, The British journal of radiology.

[9]  S. Jimenez,et al.  Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. , 2009, Arthritis and rheumatism.

[10]  T. Steger-Hartmann,et al.  Impact of Renal Impairment on Long-Term Retention of Gadolinium in the Rodent Skin Following the Administration of Gadolinium-Based Contrast Agents , 2009, Investigative radiology.

[11]  T. Frenzel,et al.  Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents , 2009, European Radiology.

[12]  M. Mack,et al.  Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[13]  T. Frenzel,et al.  Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions , 2008, European Radiology.

[14]  C. Robic,et al.  Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review , 2008, BioMetals.

[15]  T. Frenzel,et al.  A Preclinical Study to Investigate the Development of Nephrogenic Systemic Fibrosis: A Possible Role for Gadolinium-Based Contrast Media , 2008, Investigative radiology.

[16]  A. E. El Nahas,et al.  Transglutaminase inhibition reduces fibrosis and preserves function in experimental chronic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.

[17]  L. Skov,et al.  Case-control study of gadodiamide-related nephrogenic systemic fibrosis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  J. L. Abraham,et al.  Automated scanning electron microscopy and x-ray microanalysis for in situ quantification of gadolinium deposits in skin. , 2007, Journal of electron microscopy.

[19]  D. Sane,et al.  Transglutaminases: The Missing Link in Nephrogenic Systemic Fibrosis , 2007, The American Journal of dermatopathology.

[20]  S. Morcos,et al.  Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? , 2007, The British journal of radiology.

[21]  Gerald A Kirk,et al.  Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. , 2007, AJR. American journal of roentgenology.

[22]  T. Grobner.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  K. Kadler,et al.  Procollagen trafficking, processing and fibrillogenesis , 2005, Journal of Cell Science.

[24]  S. Jimenez,et al.  Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. , 2004, Arthritis and rheumatism.

[25]  V. Everts,et al.  Cytokines modulate phagocytosis and intracellular digestion of collagen fibrils by fibroblasts in rabbit periosteal explants. Inverse effects on procollagenase production and collagen phagocytosis. , 1995, Journal of cell science.

[26]  P. Wedeking,et al.  Biodistribution of Radiolabeled, Formulated Gadopentetate, Gadoteridol, Gadoterate, and Gadodiamide in Mice and Rats , 1995, Investigative radiology.

[27]  C. Evans,et al.  Collagen fibrillogenesis in the presence of lanthanides. , 1986, The Journal of biological chemistry.

[28]  C. Evans,et al.  The promotion of collagen polymerization by lanthanide and calcium ions. , 1983, The Biochemical journal.

[29]  J. Riddle,et al.  The "spindle-shaped" body in fibroblasts: intracellular collagen fibrils. , 1981, Journal of anatomy.

[30]  A. R. Cate.  Morphological studies of fibrocytes in connective tissue undergoing rapid remodelling. , 1972 .

[31]  H. Voelz.  THE "SPINDLE-SHAPED BODY" IN FIBROBLASTS , 1964, The Journal of cell biology.

[32]  J. Zic,et al.  Gadolinium deposition in nephrogenic fibrosing dermopathy. , 2007, Journal of the American Academy of Dermatology.

[33]  S. Cowper.  Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium. , 2007, Advances in dermatology.

[34]  S. Cowper,et al.  Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.

[35]  E. Uzgiris,et al.  Gadolinium determination in tissue samples by inductively coupled plasma mass spectrometry and inductively coupled plasma atomic emission spectrometry in evaluation of the action of magnetic resonance imaging contrast agents. , 1998, The Analyst.

[36]  F. Bortolotti,et al.  Human erythrocyte transglutaminase: purification and preliminary characterisation. , 1988, Biological chemistry Hoppe-Seyler.

[37]  G. Laurent,et al.  Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. , 1987, The American journal of physiology.